Global Cancer Immunotherapy Market Report 2020: Market Accounted for 50% o the Overall Oncology Drugs Market, Generating $75 Billion in 2019 and $115 Billion by 2023

News provided by

Dec 04, 2019, 10:45 ET

DUBLIN, Dec. 4, 2019 /PRNewswire/ -- The "Global Cancer Immunotherapy Market Analysis & Forecast to 2023" report has been added to ResearchAndMarkets.com's offering

Within the cancer therapeutics space, which today is worth over $100 billion globally, immunotherapeutic drugs have gained worldwide acceptance. This is because they are targeted therapeutics that have high specificity for cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $75 billion in 2019 alone and are forecast to surpass $115 billion in 2023.

Immunotherapy is forecast to become the oncology treatment of choice by 2026 with an estimated 60% of previously treated cancer patients likely to adopt immunotherapy in this timeframe. Multiple treatment lines, combination therapy and the opportunity for repeat treatment are likely to accelerate fast growth. Cancer immunotherapy also expands into multiple indications and our analysis indicates that key immunotherapies including anti-PD-1 drugs, dendritic cell vaccines, T-cell therapies, and cancer vaccines are all driving the market.

The rising incidence and prevalence of numerous cancers globally is a significant accelerator of growth. This is due to more sensitive early detection techniques, higher patient awareness, and a growing aging population. Furthermore, the FDA's pro-science attitude will accelerate development and regulatory approval for these drugs. To that end, the cancer immunotherapy market is forecast to hit $115 billion by 2023. Overall strong growth rates are expected due to a significant unmet need and increasing trends of hematological cancers.

Prior to the launching of Yervoy, the five-year survival rate for patients with early-stage melanoma was 98%; but the five-year survival rate for late-stage melanoma was just 16%. Yervoy has been reported to have a survival rate of 25% when tested alone. When tested as part of a combination therapy treatment with Bristol's nivolumab, the two-year survival rates rose to 88% for patients with late-stage cancer.

An increase in patient survival rates brought about by cancer immunotherapy treatment is similar to that seen when bone marrow transplantation changed our conception on how blood cancer was treated. Other key therapeutic players in this market include Opdivo (nivolumab), Keytruda (pembrolizumab), Tecentriq (atezolizumab), Ibrance (palbociclib) the newly approved Bavencio (avelumab) and Imfinzi (durvalumab) and of course the first CAR-T therapies Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel).

Opdivo (nivolumab) from BMS is one of the most exciting agents in the immunotherapy space and is indicated for melanoma, lung cancer, kidney cancer, blood cancer, head and neck cancer, and bladder cancer. It was given a fast-track approval on December 22, 2014. The majority of immune-oncology agents are anti-programmed death-1 (PD-1) monoclonal antibodies, which will certainly guide the market over the coming years. Projects that currently are valuable include combined immunotherapies on our knowledge of CD137 and PD-1/PDL1 mechanisms.

A study on a novel effector activating monoclonal antibody known as IMAB362 for the treatment of solid cancers is also exciting. Other projects comparing CAR-T cell effectiveness against T-cells that target CD19 or mesothelin are interesting in a preclinical setting. Of course, Novartis gained the first CAR-T FDA approval for Kymriah (tisagenlecleucel, CTL019), in August 2017, for children and young adults with B-cell ALL. In October 2017, Yescarta (axicabtagene ciloleucel) from Kite Pharma for adult patients large B-cell lymphoma was also given FDA approval. This is a major boost for the global and US immunotherapy, and gene therapy markets.

What Are CAR-T Therapies? How Will They Impact the Market?

CAR T (chimeric antigen receptor T) cells are engineered specificity using antibody fragments directed to the tumor cell, and also T-cell CD8/CD3 plasma membrane proteins that elicit specific activity towards the tumor cell, via intracellular signaling pathways. To date, publications have revealed a number of effective intracellular molecules in the engineered T cell including CD28, 4-1BB (CD137) and CD3 zeta.

These engineered T cells have numerous advantages including:

Intracellular domain can be modified to increase efficacy and durability of CAR-T
CAR-T are still subject to the same regulatory and tolerogenic constraints of natural T cells, including checkpoints, Treg, MDSC
CAR-T can be engineered to express cytokines and chemokines that further enhance function and migration
Can be modified to express suicide genes that limit CAR-T population if toxicity occurs

Key Topics Covered:

1.0 Executive Summary

2.0 Cancer Immunotherapy: An Overview

3.0 Current Status of Cancer Immunotherapy: An Overview

4.0 Challenges in Cancer Medicine Research: An Overview

5.0 Cancer Immunotherapeutic Products: An Overview

6.0 Available Immunotherapies for Cancer by Disease Type: An Overview

7.0 Cancer Incidence and Mortality: An Overview

8.0 Global Oncology Market Analysis and Forecast to 2023

9.0 Market for Cancer Immunotherapy

10.0 Company Profiles

11.0 Cancer Immunotherapy Market Participants by Product Segment

12.0 CAR T Therapy

13.0 Regulations Pertaining to Immunotherapy Regulation in the USA

14.0 Regulations for Immunotherapy in Japan

15.0 European Regulation and Immunotherapeutics

16.0 Manufacturing of Immunotherapies

17.0 Supply Chain & Logistics

18.0 Pricing & Cost Analysis

19.0 Current Deals Within the CAR T Market

20.0 CAR T Therapy Company Case Studies

Companies Mentioned

Aduro BioTech Inc
Agenus Inc
AlphaVax Inc
Amgen Inc
Antigen Express Inc
Ablation Technology
Ablynx NV
Activartis Biotech GmbH
Advaxis Inc
Argos Therapeutics Inc
AstraZeneca
Bavarian Nordic A/S
Bellicum Pharmaceuticals Inc
Biogen Idec Inc
Bristol-Myers Squibb
Bristol-Myers Squibb Company
CEL-SCI Corp.
Celgene
Celldex Therapeutics
Cellectis
CureTech Ltd.
DNAtrix Inc
Delta-Vir GmbH
DenDrit Biotech USA
Dendreon Corp.
EMD Serono Inc
Eli Lilly
Eli Lilly and Co.
Etubics Corp.
Galena Biopharma Inc
Genentech Inc
Genmab AS
GlaxoSmithKline
Gliknik Inc
GlobeImmune Inc
Heat Biologics Inc
Immatics Biotechnologies GmbH
ImmunoCellular Therapeutics Ltd.
ImmunoFrontier Inc
ImmunoGen Inc
Immunocore Ltd.
Immunomedics Inc
Immunotope Inc
Immunovaccine Inc
Inovio Pharmaceuticals Inc
Janssen Biotech Inc
Juno Therapeutics Inc
Kite Pharma Inc
MabVax Therapeutics Holdings Inc
MedImmune LLC
Merck
Merck & Co., Inc
Merrimack Pharmaceuticals Inc
Morphotek Inc
NewLink Genetics Corp.
Northwest Biotherapeutics Inc
NovaRx Corp.
Novartis
OSE Pharma SA
OncoPep Inc
Oncothyreon Inc
Oxford BioTherapeutics Ltd.
Pfizer
Pique Therapeutics
Polynoma LLC
Prima BioMed Ltd.
Progenics Pharmaceuticals Inc
Regen Biopharma Inc
Roche
Roche Holdings Inc
Seattle Genetics Inc
Sorrento Therapeutics Inc
Spectrum Pharmaceuticals Inc
Synthon Pharmaceuticals Inc
TVAX Biomedical Inc
Takeda
TapImmune Inc
ThioLogics Ltd.
Transgene SA
Vaccinogen Inc
Viventia Biotechnologies Inc
Wilex AG
Ziopharm Oncology Inc

For more information about this report visit https://www.researchandmarkets.com/r/69vbzw

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets